{"id":751051,"date":"2025-07-09T18:38:01","date_gmt":"2025-07-09T18:38:01","guid":{"rendered":"https:\/\/www.abnewswire.com\/pressreleases\/?p=751051"},"modified":"2025-07-09T18:38:01","modified_gmt":"2025-07-09T18:38:01","slug":"crohns-disease-pipeline-appears-robust-with-90-key-pharma-companies-actively-working-in-the-therapeutics-segment-delveinsight","status":"publish","type":"post","link":"https:\/\/www.abnewswire.com\/pressreleases\/crohns-disease-pipeline-appears-robust-with-90-key-pharma-companies-actively-working-in-the-therapeutics-segment-delveinsight_751051.html","title":{"rendered":"Crohn&#8217;s Disease Pipeline Appears Robust With 90+ Key Pharma Companies Actively Working in the Therapeutics Segment | DelveInsight"},"content":{"rendered":"<div style=\"float:right;  width:250px; padding:8px 10px 10px 10px;\"><a href=\"https:\/\/www.abnewswire.com\/upload\/2025\/07\/1752033827.jpg\" style=\"border:none !important;\" target=\"_blank\" rel=\"nofollow\" ><img loading=\"lazy\" decoding=\"async\" class=\"alignnone size-medium wp-image-29\" title=\"Crohn&#039;s Disease Pipeline Appears Robust With 90+ Key Pharma Companies Actively Working in the Therapeutics Segment | DelveInsight\" src=\"https:\/\/www.abnewswire.com\/upload\/2025\/07\/1752033827.jpg\" alt=\"Crohn&#039;s Disease Pipeline Appears Robust With 90+ Key Pharma Companies Actively Working in the Therapeutics Segment | DelveInsight\" width=\"225\" height=\"225\" \/><\/a><\/div>\n<p style=\"text-align: justify;\">DelveInsight&rsquo;s, &ldquo;<strong>Crohn&rsquo;s Disease Pipeline Insight 2025<\/strong>&rdquo; report provides comprehensive insights about 90+ companies and 90+ pipeline drugs in Crohn&rsquo;s Disease pipeline landscape. It covers the <strong>Crohn&#8217;s Disease pipeline drug<\/strong> profiles, including clinical and nonclinical stage products. It also covers the <strong>Crohn&#8217;s Disease pipeline<\/strong> <strong>therapeutics<\/strong> assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.<\/p>\n<p style=\"text-align: justify;\"><strong>Explore the comprehensive insights by DelveInsight and stay ahead in understanding the Crohn&#8217;s Disease Treatment Landscape. Click here to read more @ <a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/sample-request\/crohns-disease-pipeline-insight?utm_source=abnewswire&amp;utm_medium=pressrelease&amp;utm_campaign=ypr\">Crohn&#8217;s Disease Pipeline Outlook<\/a><\/strong><\/p>\n<p style=\"text-align: justify;\"><strong>Key Takeaways from the Crohn&#8217;s Disease Pipeline Report<\/strong><\/p>\n<ul style=\"text-align: justify;\">\n<li><strong><em>In July 2025, AbbVie<\/em><\/strong> conducted a study will evaluate the effectiveness and adverse events of targeted therapies (TaTs) for adult participants with moderate to severe CD. Crohn&#8217;s disease (CD) is a long-lasting disease that causes severe inflammation (redness, swelling), in the digestive tract, most frequently affecting the bowels. It can cause many different symptoms including belly pain, diarrhea, tiredness, and weight loss. Treatments are available but do not work the same for all patients or may stop working over time.<\/li>\n<li><strong><em>In July 2025, Sanofi<\/em><\/strong> announced a study for the treatment of Crohn&#8217;s disease. The primary objective of this study is to assess the efficacy of different doses of SAR442970 compared with placebo in participants with moderate to severe Crohn&#8217;s disease. The total study duration is up to 168 weeks, with a treatment period of up to 158 weeks including an open-label (OL) long-term extension (LTE) period of up to 104 weeks for eligible participants<\/li>\n<li><strong><em>In July 2025, Janssen Research &amp; Development LLC <\/em><\/strong>organized a study is to evaluate the clinical and endoscopic efficacy of guselkumab in pediatric participants with Crohn&#8217;s Disease (CD) at the end of maintenance therapy (Week 52) among participants who were in clinical response to guselkumab at Week 12.<\/li>\n<li><strong><em>In July 2025, Eli Lilly and Company<\/em><\/strong> announced a study participants will be screened during the platform study and randomly assigned to receive mirikizumab or another intervention. The purpose of the mirikizumab study is to evaluate efficacy, safety, tolerability, and how well mirikizumab absorbs into the body of pediatric participants with Crohn&#8217;s disease.<\/li>\n<li>DelveInsight&rsquo;s <strong>Crohn&#8217;s Disease pipeline report<\/strong> depicts a robust space with 90+ active players working to develop 90+ pipeline therapies for Crohn&#8217;s Disease treatment.<\/li>\n<li>The leading Crohn&#8217;s Disease companies such as <strong><em>Janssen, RedHill Biopharma, Amgen, Pfizer, Hoffmann-La Roche, Gilead Sciences, Eli Lilly and Company, Celgene, AstraZeneca, AbbVie, Mesoblast, Alfasigma, Tiziana Life Sciences, Abivax, Arena Pharmaceuticals, Cytocom, Priothera, SLA Pharma, HAV Vaccines Ltd, Enzo Biochem Inc., VHsquared Ltd., Stero Biotechs, Reistone Biopharma Company Limited, Qu Biologics, Provention Bio, Mitsubishi Tanabe Pharma Corporation, Takeda Pharmaceuticals, Soligenix, Immunic, Atlantic Healthcare, 4D Pharma, Landos Biopharma, Protagonist Therapeutics, Roche, Eisai, Bristol-Myers Squibb, Iltoo Pharma, Fast Forward Pharmaceuticals, Suzhou Connect Biopharmaceuticals, Theravance Biopharma, TaiwanJ Pharmaceuticals, Active Biotech, Celularity, Cerecor, GlaxoSmithKline, Kang Stem Biotech, Alpha Cancer Technologies, Koutif Therapeutics, Winston Pharmaceuticals, Tract Therapeutics, Trio Medicines, Tetherex Pharmaceuticals, ChemoCentryx, Algernon Pharmaceuticals, Neuclone, Innovimmune Biotherapeutics, JHL Biotech, Intract Pharma Ltd, Innovative Pharmacological Research (IPHAR) Co Ltd, Innovation Pharmaceuticals, Exeliom Biosciences SAS, Finch Therapeutics, Akeso Biopharma, Draconis Pharma, MakScientific, Origo Biopharma, Navidea Biopharmaceuticals, Orchard Therapeutics, Xbrane, Thetis Pharmaceuticals, Temisis Therapeutics, Synedgen, Synlogic, PlantPraxis, Morphic Therapeutic, Metacrine, Curacle, Commence Bio Inc, Cloud Pharmaceuticals, Chong Kun Dang Pharmaceutical Corp, Avobis Bio LLC, Avexegen Therapeutics, Atlantic Bio Sci, Assembly Biosciences, Artelo Biosciences, Aibios Co Ltd, Aclaris Therapeutics, Athos Therapeutics, Denali Therapeutics, Educell doo<\/em><\/strong> and others.<\/li>\n<li>Promising Crohn&rsquo;s Disease Pipeline Therapies such as <strong><em>Etrasimod, Infliximab, MEDI2070, Filgotinib, Risankizumab 600 mg IV, CT-P13<\/em><\/strong>, and others.<\/li>\n<\/ul>\n<p style=\"text-align: justify;\"><strong>Discover groundbreaking developments in Crohn&#8217;s Disease therapies! Gain in-depth knowledge of key Crohn&#8217;s Disease clinical trials, emerging drugs, and market opportunities @ <a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/sample-request\/crohns-disease-pipeline-insight?utm_source=abnewswire&amp;utm_medium=pressrelease&amp;utm_campaign=ypr\">Crohn&#8217;s Disease Clinical Trials Assessment<\/a><\/strong><\/p>\n<p style=\"text-align: justify;\"><strong>Crohn&#8217;s Disease Emerging Drugs Profile<\/strong><\/p>\n<ul style=\"text-align: justify;\">\n<li><strong>Guselkumab: Janssen<\/strong><\/li>\n<\/ul>\n<p style=\"text-align: justify;\">Guselkumab is a human immunoglobulin G1 lambda (IgG1&lambda;) monoclonal antibody that selectively blocks interleukin-23. IL-23 is an inflammatory cytokine that activates the CD4+ T-helper (Th17) cell pathway to mediate the inflammatory cascade that induces psoriatic plaque formation. In clinical trials, guselkumab demonstrated improved skin clearance and symptomatic improvements in dermatological manifestations of psoriasis. It is currently in Phase III of clinical trial.<\/p>\n<ul style=\"text-align: justify;\">\n<li><strong>RHB-104: RedHill Biopharma<\/strong><\/li>\n<\/ul>\n<p style=\"text-align: justify;\">RHB-104 is a potentially groundbreaking, proprietary investigational drug in oral capsule formulation, with potent intracellular, antimycobacterial and anti-inflammatory properties. It is currently in Phase III of clinical trial.<\/p>\n<p style=\"text-align: justify;\"><strong>Crohn&#8217;s Disease Market Drivers<\/strong><\/p>\n<ul style=\"text-align: justify;\">\n<li>Increasing Prevalence of Inflammatory Bowel Disease<\/li>\n<li>Development of New and Effective Therapies<\/li>\n<\/ul>\n<p style=\"text-align: justify;\"><strong>Crohn&#8217;s Disease Market Barriers<\/strong><\/p>\n<ul style=\"text-align: justify;\">\n<li>Limited awareness and education<\/li>\n<li>Failures and discontinuation of emerging therapies<\/li>\n<\/ul>\n<p style=\"text-align: justify;\"><strong>The Crohn&rsquo;s Disease Pipeline Report Provides Insights into<\/strong><\/p>\n<ul style=\"text-align: justify;\">\n<li>The report provides detailed insights about companies that are developing therapies for the treatment of Crohn&rsquo;s Disease with aggregate therapies developed by each company for the same.<\/li>\n<li>It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Crohn&rsquo;s Disease Treatment.<\/li>\n<li>Crohn&rsquo;s Disease Companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.<\/li>\n<li>Crohn&rsquo;s Disease Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.<\/li>\n<li>Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Crohn&rsquo;s Disease market<\/li>\n<\/ul>\n<p style=\"text-align: justify;\"><strong>Stay informed about the Crohn&#8217;s Disease pipeline trends! Uncover critical updates on therapeutic innovations and their potential impact on patients and the healthcare industry @ <a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/sample-request\/crohns-disease-pipeline-insight?utm_source=abnewswire&amp;utm_medium=pressrelease&amp;utm_campaign=ypr\">Crohn&#8217;s Disease Unmet Needs<\/a><\/strong><\/p>\n<p style=\"text-align: justify;\"><strong>Crohn&#8217;s Disease Companies<\/strong><\/p>\n<p style=\"text-align: justify;\">Janssen, RedHill Biopharma, Amgen, Pfizer, Hoffmann-La Roche, Gilead Sciences, Eli Lilly and Company, Celgene, AstraZeneca, Abbvie, Mesoblast, Alfasigma, Tiziana Life Sciences, Abivax, Arena Pharmaceuticals, Cytocom, Priothera, and others.<\/p>\n<p style=\"text-align: justify;\"><strong>Crohn&rsquo;s Disease pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as<\/strong><\/p>\n<ul style=\"text-align: justify;\">\n<li>Oral<\/li>\n<li>Intravenous<\/li>\n<li>Subcutaneous<\/li>\n<li>Parenteral<\/li>\n<li>Topical<\/li>\n<\/ul>\n<p style=\"text-align: justify;\"><strong>Crohn&#8217;s Disease Products have been categorized under various Molecule types such as<\/strong><\/p>\n<ul style=\"text-align: justify;\">\n<li>Recombinant fusion proteins<\/li>\n<li>Small molecule<\/li>\n<li>Monoclonal antibody<\/li>\n<li>Peptide<\/li>\n<li>Polymer<\/li>\n<li>Gene therapy<\/li>\n<\/ul>\n<p style=\"text-align: justify;\"><strong>Transform your understanding of the Crohn&#8217;s Disease Pipeline! See the latest progress in drug development and clinical research @ <a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/sample-request\/crohns-disease-pipeline-insight?utm_source=abnewswire&amp;utm_medium=pressrelease&amp;utm_campaign=ypr\">Crohn&#8217;s Disease Market Drivers and Barriers, and Future Perspectives<\/a><\/strong><\/p>\n<p style=\"text-align: justify;\"><strong>Scope of the Crohn&#8217;s Disease Pipeline Report<\/strong><\/p>\n<ul style=\"text-align: justify;\">\n<li>Coverage- Global<\/li>\n<li>Crohn&#8217;s Disease Companies- <strong><em>Janssen, RedHill Biopharma, Amgen, Pfizer, Hoffmann-La Roche, Gilead Sciences, Eli Lilly and Company, Celgene, AstraZeneca, Abbvie, Mesoblast, Alfasigma, Tiziana Life Sciences, Abivax, Arena Pharmaceuticals, Cytocom, Priothera,<\/em><\/strong> and others.<\/li>\n<li>Crohn&rsquo;s Disease Pipeline Therapies- <strong><em>Etrasimod, Infliximab, MEDI2070, Filgotinib, Risankizumab 600 mg IV, CT-P13,<\/em><\/strong> and others.<\/li>\n<li>Crohn&#8217;s Disease Therapeutic Assessment by Product Type: Mono, Combination, Mono\/Combination<\/li>\n<li>Crohn&#8217;s Disease Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III<\/li>\n<\/ul>\n<p style=\"text-align: justify;\"><strong>&#8220;Stay Ahead in Gastroenterology Research&ndash;Access the Full Crohn&#8217;s Disease Pipeline Analysis Today! @ <a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/sample-request\/crohns-disease-pipeline-insight?utm_source=abnewswire&amp;utm_medium=pressrelease&amp;utm_campaign=ypr\">Crohn&#8217;s Disease Drugs and Companies<\/a><\/strong><\/p>\n<p style=\"text-align: justify;\"><strong>Table of Content<\/strong><\/p>\n<ol style=\"text-align: justify;\">\n<li>Introduction<\/li>\n<li>Crohn&#8217;s Disease Executive Summary<\/li>\n<li>Crohn&rsquo;s Disease: Overview<\/li>\n<li>Crohn&#8217;s Disease Pipeline Therapeutics<\/li>\n<li>Crohn&#8217;s Disease Therapeutic Assessment<\/li>\n<li>Crohn&rsquo;s Disease&ndash; DelveInsight&rsquo;s Analytical Perspective<\/li>\n<li>Late Stage Products (Phase III)<\/li>\n<li>Ozanimod: Bristol-Myers Squibb<\/li>\n<li>Drug profiles in the detailed report&hellip;..<\/li>\n<li>Mid Stage Products (Phase II)<\/li>\n<li>CBP-307: Suzhou Connect Biopharmaceuticals<\/li>\n<li>Drug profiles in the detailed report&hellip;..<\/li>\n<li>Early Stage Products (Phase I)<\/li>\n<li>IMU-856: Immunic<\/li>\n<li>Drug profiles in the detailed report&hellip;..<\/li>\n<li>Preclinical and Discovery Stage Products<\/li>\n<li>Drug name: Company name<\/li>\n<li>Drug profiles in the detailed report&hellip;..<\/li>\n<li>Inactive Products<\/li>\n<li>Crohn&rsquo;s Disease Key Companies<\/li>\n<li>Crohn&rsquo;s Disease Key Products<\/li>\n<li>Crohn&rsquo;s Disease- Unmet Needs<\/li>\n<li>Crohn&rsquo;s Disease- Market Drivers and Barriers<\/li>\n<li>Crohn&rsquo;s Disease- Future Perspectives and Conclusion<\/li>\n<li>Crohn&rsquo;s Disease Analyst Views<\/li>\n<li>Crohn&rsquo;s Disease Key Companies<\/li>\n<li>Appendix<\/li>\n<\/ol>\n<p style=\"text-align: justify;\"><strong>About Us<\/strong><\/p>\n<p style=\"text-align: justify;\">DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.<\/p>\n<p><span style='font-size:18px !important;'>Media Contact<\/span><br \/><strong>Company Name:<\/strong> <a href=\"https:\/\/www.abnewswire.com\/companyname\/delveinsight.com_56402.html\" rel=\"nofollow\">DelveInsight Business Research LLP<\/a><br \/><strong>Contact Person:<\/strong> Yash Bhardwaj<br \/><strong>Email:<\/strong> <a href=\"https:\/\/www.abnewswire.com\/email_contact_us.php?pr=crohns-disease-pipeline-appears-robust-with-90-key-pharma-companies-actively-working-in-the-therapeutics-segment-delveinsight\" rel=\"nofollow\">Send Email<\/a><br \/><strong>Phone:<\/strong> 09650213330<br \/><strong>Address:<\/strong>304  S. Jones Blvd #2432<br \/><strong>City:<\/strong> Las Vegas<br \/><strong>State:<\/strong> NV<br \/><strong>Country:<\/strong> United States<br \/><strong>Website:<\/strong> <a href=\"https:\/\/www.delveinsight.com\/report-store\/crohns-disease-pipeline-insight\" target=\"_blank\" rel=\"nofollow\">https:\/\/www.delveinsight.com\/report-store\/crohns-disease-pipeline-insight<\/a><\/p>\n<p><img decoding=\"async\" src=\"https:\/\/www.abnewswire.com\/press_stat.php?pr=crohns-disease-pipeline-appears-robust-with-90-key-pharma-companies-actively-working-in-the-therapeutics-segment-delveinsight\" alt=\"\" width=\"1px\" height=\"1px\" \/><\/p>\n","protected":false},"excerpt":{"rendered":"<p>DelveInsight&rsquo;s, &ldquo;Crohn&rsquo;s Disease Pipeline Insight 2025&rdquo; report provides comprehensive insights about 90+ companies and 90+ pipeline drugs in Crohn&rsquo;s Disease pipeline landscape. It covers the Crohn&#8217;s Disease pipeline drug profiles, including clinical and nonclinical stage products. It also covers the &hellip; <a href=\"https:\/\/www.abnewswire.com\/pressreleases\/crohns-disease-pipeline-appears-robust-with-90-key-pharma-companies-actively-working-in-the-therapeutics-segment-delveinsight_751051.html\">Continue reading <span class=\"meta-nav\">&rarr;<\/span><\/a><\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[401,435,405,406],"tags":[],"class_list":["post-751051","post","type-post","status-publish","format-standard","hentry","category-Business","category-Europe","category-Health-Medicine","category-Pharmaceuticals-Biotech"],"_links":{"self":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/posts\/751051","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/comments?post=751051"}],"version-history":[{"count":0,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/posts\/751051\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/media?parent=751051"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/categories?post=751051"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/tags?post=751051"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}